阿佩林-13:一种新的方法来抑制RVHT中的氨酸生产
Ziqing Yan1, Teng Yang1, Xinxuan Li1
1School of PharmacyWeifang Medical University, Weifang, Shandong, China.
American journal of physiology. Cell physiology
|April 22, 2024
概括
阿佩林-13通过抑制cAMP/PKA/可溶性 (pro) renin受体通路,有效降低宁在血管高血压中的产生. 这一发现为治疗RVHT提供了一个有希望的新疗法策略.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 腎病理生理學 腎病理生理學
背景情况:
- 血管高血压 (RVHT) 涉及动脉狭窄和过度激活的氨酸-血管新生素系统 (RAS).
- 阿佩林是一种RAS调节剂,显示出心血管保护作用,但其在RVHT中的作用尚未完全理解.
- 在RVHT中,阿佩林的活性形式阿佩林-13的特定机制需要进一步研究.
研究的目的:
- 调查apelin-13在血管高血压 (RVHT) 的大鼠模型中的作用和潜在机制.
- 探索阿佩林-13对氨酸生产和可溶性 (pro) 氨酸受体 (sPRR) 途径的影响.
- 评估apelin-13作为RVHT的潜在治疗剂.
主要方法:
- 建立了RVHT.的双脏单片 (2K1C) 鼠标模型.
- 给2K1C大鼠服用阿佩林-13并分析了宁表达, (pro) 宁受体 (PRR) 水平和cAMP信号传递.
- 利用细胞培养 (Calu-6,As4.1) 来研究氨酸生产调节和阿佩林-13,CREB抑制和sPRR的影响.
主要成果:
- 在2K1C大鼠中,阿佩林-13治疗显著降低了缩血压升高,血二含量,二活性 (PRA),血管新生素II (ANG II) 和sPRR水平.
- 阿佩林-13抑制了氨酸mRNA和蛋白质表达,cAMP的产生,以及脏组织中的PRR/sPRR蛋白水平.
- 实验室研究表明,阿佩林-13通过cAMP/PKA/CREB/sPRR通路抑制了cAMP诱导的fPRR/sPRR表达和蛋白生产.
结论:
- 阿佩林-13通过向cAMP/PKA/可溶性 (pro) renin受体通路来抑制RVHT中的宁产生.
- 这些发现突出了阿佩林-13作为RVHT新治疗策略的潜力,通过调节蛋白表达来调节RVHT.
- 了解蛋白生产调节对于开发有效的RVHT治疗至关重要.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
613
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156